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SPECIAL ARTICLE
ICF Core Sets: how to specify impairment 
and function in systemic lupus erythematosus
M Aringer1*, TA Stamm1–3, DS Pisetsky4,5, CH Yarboro6, A Cieza2, JS Smolen1,7, G Stucki2,3
1Department of Rheumatology, Internal Medicine III, Medical University of Vienna Austria; 2ICF Research Branch of 
the WHO Collaborating Center for the Family of International Classifications at the German Institute of 
Medical Documentation and Information (DIMDI), IMBK, Munich, Germany; 3Department of Physical 
Medicine and Rehabilitation, Ludwig-Maximilians-University, Munich, Germany; 4 Medical Research 
Service, Durham VA Hospital, Durham, NC, USA; 5 Division of Rheumatology and Immunology,
Duke University Medical Center, Durham, NC, USA; 6 National Institute of 
Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, USA; and
7 Department of Medicine II, Lainz Hospital, Vienna, Austria
The World Health Organization’s International Classification of Function (ICF) is a tool to
characterize and illuminate better the full of array of problems a patient faces when affected by
disease. Specifying these problems is a particular challenge in a disease like systemic lupus
erythematosus (SLE) because of the wide variety in organ systems involved, its variable activity
and severity, and considerable ethnic and local differences. The authors of this manuscript believe,
however, that a broader understanding will prove essential for optimal patient care, and that there
is sufficient experience now in defining ICF Core Sets to successfully complete core sets for SLE.
Therefore, we will embark on an international project for developing ICF Core Sets for SLE,
which we here delineate. This development will include two versions: 1) The Brief ICF Core Set
for SLE will be a very focused list of categories essential for SLE clinical trials; and 2) The
Comprehensive ICF Core Set will be much broader and useful for guiding multidisciplinary
assessment in patients with SLE. Both Core Sets will be developed in a formal decision-making
and consensus process of health professionals integrating evidence gathered from preliminary
studies. The final definition of the Core Sets will occur at a consensus conference which will
integrate: i) a systematic review of the literature regarding the outcome measures used in clinical
trials and selected observational studies; ii) focus groups or semi-structured interviews with SLE
patients; iii) a Delphi exercise with world wide involvement of experts; and iv) the evidence from
empirical studies. The development of these SLE ICF Core Sets is designed to be an inclusive,
open, worldwide process. We therefore invite both SLE clinical experts and SLE patients to
participate actively. Lupus (2006) 15, 248–253.
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Introduction
Comprehending the problems faced by patients with a
given disease is an essential aspect of medical care,
although always a challenge. Health professionals, in
general, and physicians, in particular, tend to focus on
a limited number of parameters that can be readily
measured. While this approach is appropriate for deter-
mining organ involvement and disease activity as well
as making therapeutic decisions, it can fall short when
evaluating over-all patient well-being or disease-related
cost. Exploring the perspective of patients is particu-
larly important in a heterogeneous disease such as sys-
temic lupus erythematosus (SLE), because individual
patient problems may vary greatly in severity and dura-
tion. Thus, ideally, an outcome measurement should
provide a comprehensive picture of the different prob-
lems experienced by the individual patient, and should
not only focus on biomedical outcome measures.
Achieving such a comprehensive view of SLE
patients’ problems will be a difficult task. Why then
should rheumatologists take on such challenge? Since,
despite considerable work, such endeavour might pro-
duce a useful outcome, what is there to gain? There are
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several answers to these important questions, which,
we think, will stand in the end. One of the answers
comes from occupational therapy, where function and
disability are the main focus of attention. While physi-
cians uncommonly focus on disability in their profes-
sional approach, but rather on stopping disease from
causing disability, occupational therapists are trained
to mainly see this other side of the patient. By doing
so, however, occupational therapists and other health
professionals will need our effort to set the stage for
optimal patient care. It is the physicians and nurses, on
the one hand, and the patients, on the other, who know
intimately about the manifestations of SLE, and can
therefore link the available information into a mean-
ingful framework.
In addition to providing the information for a solid
background for all health professionals, a comprehen-
sive definition of the problems faced by SLE patients
will be a powerful tool for dealing with both politics
and decisions by health authorities. While very impor-
tant on an emotional level, the example of single cases
can never substitute for such data. If we do not under-
stand the variety of problems our patients face, there is
little we can do about them on either a medical level or
on a political one. Moreover, applying comprehensive
models of functioning and health will be the base for a
true assessment of the burden of disease. These com-
prehensive models will then allow comparisons
between different diseases, and lead political decision
makers to informed decisions with regard to the allo-
cation of resources, laws, and care provision.
Finally, such a comprehensive understanding will
hopefully lead to better tools for daily practice. Fatigue
scales for example, have found their way into lupus
trials and care,1 although derived from outside our own
field. It is important that neither fatigue nor quality of
life measures were found associated with SLE disease
activity in cross-sectional studies,2 suggesting that
important aspects of the lupus patient’s disease burden –
potentially including treatable conditions – are not
responding to treatment despite intensive medical care
for internal organ disease. Along similar lines, we may
want to develop a lupus skin score showing the
patient’s view on disease-related problems. Such a
score could become be a valuable tool for guiding ther-
apeutic efforts to control skin manifestations of SLE or
cutaneous lupus. After all, it is the impaired function of
a patient in daily life, and the ensuing loss in life qual-
ity, that will influence patient decisions about accept-
ing the risks or side effects for specific treatments.
These concepts pertain for practically any given
disease, and the World Health Assembly has there-
fore responded by approving the new International
Classification of Functioning (ICF),3 the first univer-
sally accepted way to classify and describe functioning,
disability and health in persons with a condition.
Following the WHO definition of health, the ICF
framework is based on the bio-psycho-social model.
The ICF models daily functioning of patients with
different health conditions within the framework of a
classification. Thus, the ICF offers a frame of reference
to describe the functioning of patients with a certain
health condition.
Technically, the ICF classification has two parts,
each consisting of separate components. Part 1 covers
functioning and disability and includes the compo-
nents body functions (b) and structures (s) as well as
daily activities and participation (d). Part 2 covers the
context, comprising environmental (e) and personal
factors. Each component is divided into several chap-
ters, which represent health domains. Examples are the
chapter neuromusculoskeletal and movement-related
functions within the component body functions and the
chapter self-care within the component activity and
participation. Each chapter then consists of categories,
which are the factual units of the classification.3
In total, the ICF classification includes more than
1400 categories, thus limiting use in clinical practice.
It is possible, however, to derive practical tools from
the classification, which are called ICF Core Sets.4,5
ICF Core Sets are short lists of selected ICF categories,
which are useful for modelling the function of patients
with a specific disease. To date, ICF Core Sets have
been developed for 12 chronic conditions.6,7 The one
example in rheumatology is the ICF Core Set for
rheumatoid arthritis.8 Core Sets for several other
chronic conditions are currently being developed.
It is important to reiterate that the ICF is a frame-
work, and the ICF Core Sets are practical tools to clas-
sify and describe patient functioning, using a
classification of world-wide acceptance. However, at
this point, the categories included in ICF core sets do
not define the basis of measurement. Instead, the ICF
Core Sets can serve as reference framework when
selecting instruments for measuring symptoms and
consequences of the disease, or when defining the ele-
ments covered by specific measures. The ICF and the
ICF Core Sets may become the base for further devel-
oping such measures. In this way, the ICF is an impor-
tant concept and ICF Core Sets are interesting tools for
the further development of clinical (and rehabilitation)
science.
The development of ICF Core Sets for SLE poses
considerable complexities and even obstacles. SLE is
prototypically a heterogenous disease, perhaps even
more so than other multisystem disorders. Not only is
there a wide range of both disease activity and sever-
ity, but therapy varies markedly in intensity as well as
toxicity, all of which can influence patient outcomes.
SLE involves essentially all organ systems, including
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the CNS, and may induce various functional problems
as well as damage in the brain. The various possible
CNS manifestations of the disease, and their treatment,
will further add to the heterogeneity of problems faced
by SLE patients. On the other hand, there are typical
symptoms which will afflict most SLE patients,
regardless of their main organ manifestations.
Therefore, ICF Core Sets for SLE will need to address
the full spectrum of problems encountered both with
SLE in general, and with the most common forms of
SLE organ involvement in particular. We expect that
there will be overlapping core sets with other diseases
afflicting the same organ system, such as between SLE
with lupus arthritis and rheumatoid arthritis, or
between SLE renal disease and other forms of
glomerulonephritis.
The most commonly used measures in SLE are
activity scores, such as (in alphabetical order) the
British Isles Lupus Assessment Group index
(BILAG),9 the European Consensus Lupus Activity
Measurement (ECLAM),10 the SLE Index Score
(SIS),11 the Systemic Lupus Activity Measure
(SLAM),12 or the SLE Disease Activity Index
(SLEDAI).13 All of these scores contain information
on a variety of symptoms experienced by the patient
(Table 1), in addition to a variety of laboratory and
other parameters.
Regarding these symptoms, there are important
differences among the organ systems affected. For
example, general, mucocutaneous, or neurological
symptoms receive prominent attention, whereas other
important organ manifestations are scarcely consid-
ered (Table 1). In part, this relative imbalance is due to
a lack of symptoms, such as often is the case in early
renal disease, although the activity measures account
for such manifestation by using laboratory evaluations
instead. Also, the symptoms graded here serve the pur-
pose of indicating activity; they do not weigh damage
or well-being, and some are quite uncommon features.
In addition to the activity scales, which
correlate well with each other,14 there is one well-
established SLE damage index, the Systemic Lupus
International Collaborative Clinics/American College
of Rheumatology (SLICC/ACR) damage index.15
Moreover, several non-specific quality of life-
measures have been successfully used in patients with
SLE.1,2 While useful in pointing to candidate ICF
categories, these indices, however, will neither allow
for functional measurement nor will they directly
indicate the most relevant categories in understanding
the functional disease burden of SLE.
To meet the need for new outcomes measures for
SLE, we here propose a process to lead to comprehen-
sive ICF core sets for patients with SLE. While this plan
was first derived in a meeting conducted in Munich in
November 2004, and bolstered after interactions with
several other centres, we would like to invite worldwide
participation in this effort. Only by cooperation and
exchange can we can reach the goal of developing ICF
core sets for SLE (and possibly including isolated cuta-
neous lupus) to depict comprehensively the functional
problems faced by patients all over the world, including
their many diverse and confusing variations.
Methodological approach to develop 
ICF Core Sets for SLE
Types of ICF Core Sets that will be developed
The development of ICF Core Sets for SLE will
include two versions: The Brief ICF Core Set for SLE
to be used in clinical trials. Thus, the Brief ICF Core
Set for SLE will include a list of ICF categories with
as few categories as possible to be practical, but as
many as necessary to describe as comprehensively as
possible the spectrum of problems in functioning of
patients with SLE for clinical studies.
The Comprehensive ICF Core Set will be applicable
for guiding multidisciplinary assessment in patients
with SLE. Thus, more ICF categories will need to be
included to adequately describe, in a multidisciplinary
assessment, the typical spectrum of problems in func-
tioning of any patient with SLE. Two additional add-on
ICF Core Sets Lists will be developed. The first will be
for mucocutaneous manifestations, while the second
will be for musculoskeletal involvement, the latter based
on the existing core set for rheumatoid artritis (RA).
Based on knowledge gained in the previous ICF
Core Set developments, the following methodological
approach for the Core Set development is projected.
Study design
As is the standard procedure for the ICF Core Sets, the
SLE core sets will be defined at a consensus confer-
ence, which will integrate i) a systematic review of the
literature regarding the outcome measures used in clin-
ical trials and selected observational studies, ii) focus
groups or semi-structured interviews with SLE
patients, iii) a Delphi exercise with world wide
involvement of experts, and iv) empirical studies.
With this study design, all relevant perspectives
should be adequately addressed. The patient perspec-
tive, which is crucial to the success of the project, is
addressed both in a qualitative way in focus groups and
in a quantitative way in the empirical studies. In addi-
tion, we will try to initiate a Delphi exercise for
patients. The investigator perspective is addressed in
the systematic literature reviews. Finally, various
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Table 1 Symptoms (not objective parameters) rated in commonly used SLE activity scores
Organ system Symptom Score ICF Description
Constitutional/general Anorexia/nausea/vomiting BILAG b530 Weight maintenance functions 
b5350 Sensation of nausea Regurgitation
b5106 and vomiting
Fatigue BILAG, ECLAM,
SIS, SLAM b130 Energy & drive functions
b4552 Fatiguability
Fever/pyrexia BILAG, ECLAM,
SIS, SLAM, SLEDAI nd
Lymphadenopathy BILAG, SIS, SLAM s4201 Structure of lymphatic nodes
Splenomegaly BILAG, SLAM s4203 Spleen
Weight loss BILAG, SLAM b530 Weight maintenance functions
Mucocutaneous Alopecia BILAG, ECLAM, SIS,
SLAM, SLEDAI b850 Functions of hair
Angio-oedema BILAG b4351 Hypersensitivity reactions
Calcinosis BILAG s898 Skin and related structures, other 
specified: calcinosis
Mucosal ulcers BILAG, ECLAM,
SIS, SLAM, SLEDAI b810 Protective functions of the skin
Panniculitis BILAG b820 Repair functions of the skin
Sclerodactyly BILAG b810 Protective functions of the skin
b820 Repair functions of the skin
Skin rash BILAG, ECLAM,
SIS, SLAM, SLEDAI b810 Protective functions of the skin
Skin ulcers BILAG, SIS, SLAM,
SLEDAI b810 Protective functions of the skin
Musculoskeletal Arthralgias BILAG, ECLAM,
SIS, SLAM b28016 Pain in joints
Arthritis BILAG, ECLAM, SIS,
SLAM, SLEDAI s7701 Joints
b28016 Pain in joints
b710 Mobility of joint functions
b715 Stability of joint functions
Aseptic necrosis BILAG s7700 Bones
s7701 Joints
Contractures BILAG b710 Mobility of joint functions
Myalgias BILAG, SIS, SLAM b28018
Pain in body part, other specified:
muscle
Muscle weakness SIS, SLAM,
SLEDAI b730 Muscle power functions
Tendonitis/tendosynovitis BILAG, SLAM s73023 Ligaments and fasciae of hand
Neurological Cerebellar ataxia BILAG b7602 Coordination of voluntary
movements
Chorea BILAG, SLAM b7650 Involuntary contractions of
muscles
Cranial nerve disorder BILAG, SIS,
SLAM, SLEDAI s1106 Structure of cranial nerves
Depression BILAG, ECLAM,
SIS, SLAM, SLEDAI b152 Emotional functions
Headache BILAG, ECLAM,
SLAM, SLEDAI b28010 Pain in head and neck
Mononeuritis multiplex BILAG, SIS, SLAM b280 Sensation of pain
b265 Touch functions
b270 Sensory functions related to
temperature & other stimuli
Organic brain syndrome BILAG, ECLAM,
SIS, SLAM, SLEDAI b1102 Quality of consciousness
b114 Orientation functions
b152 Emotional functions
Psychosis BILAG, ECLAM,
SIS, SLAM, SLEDAI b1102 Quality of consciousness
b114 Orientation functions
b152 Emotional functions
Seizures BILAG, ECLAM,
SIS, SLAM, SLEDAI s1100 Structure of cortical lobes
nd
(Continued)
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expert opinions involving professionals from different
backgrounds shape the Delphi exercise, as well as the
final conference.
Consensus conference
The consensus conference is scheduled for Vienna in
mid-2007. Experts in the field of SLE will work
together actively to select the ICF categories for the
Comprehensive and the Brief Core Set. Based on
previous experience, it is proposed to form three groups
with seven experts each, including different health pro-
fessionals, who can work together in the spirit of the
multi-professional and multi-disciplinary approach typ-
ical for care and research in SLE. The method selected
to regulate the group dynamic and the teamwork during
the conference is the ‘Nominal-Group Technique’.16
Evidence from empirical studies
A systematic review of the concepts of outcome meas-
ures used in published studies17 is being performed.
The objectives of the systematic review are to identify
outcome measures cited in published studies focusing
on individuals with SLE, and to quantify the concepts
contained in these measures. The concepts of the
retrieved outcome measures will be linked to ICF cat-
egories using standardized linking rules.18 The results
from this systematic review of empirical studies
should be available in June 2006.
Focus groups with patients
‘Focus groups’, ie, open interviews with patients in
small groups of up to seven people, have been chosen
as the most appropriate available qualitative approach
for identifying the patient perspective of functioning
and health.19,20 As compared to individual interviews,
focus groups are enriched by interactions in the 
group, and therefore usually generate additional 
information. Focus group studies will at least be per-
formed in Europe (Austria) as well as in the US and
East Asia. These groups should be completed by the
end of August 2006, so that their results can be
included in the Delphi exercise and empirical studies
(below).
Delphi exercise
A Delphi exercise will encourage experts to identify
problems they appreciate for their patients in a feed-
back procedure based on information-technology,21
with the goal of shaping common consensus. Balanced
involvement with regard to WHO regions and profes-
sions will be facilitated by directly approaching
experts from both underrepresented areas (eg, Africa,
South America) and fields (eg, psychologists, physio-
therapists). Delphi exercises will start in September
2006, and should be finished by January 2007. We will
try to also initiate an SLE patient Delphi exercise with
a similar approach.
Stroke symptoms BILAG, ECLAM, SIS,
SLAM, SLEDAI s110
Structure of brain
nd
Transverse myelitis BILAG, SLAM s120 Structure of spinal cord
nd
Visual disturbance BILAG, SLAM,
SLEDAI b210 Seeing functions
Pulmonary Arrhythmias BILAG b4101 Heart rhythm
Cardiovascular Dyspnoea BILAG, ECLAM,
SLAM b440 Respiratory functions
Phlebitis BILAG s4102 Veins
Pleuropericardial pain BILAG, ECLAM, SIS,
SLAM, SLEDAI b28011 Pain in chest
Raynaud’s BILAG, ECLAM,
SIS, SLAM b415 Blood vessel functions
Thromboembolism BILAG, SIS b430 Haematological system functions
Abdominal Abdominal vasculitic crisis BILAG, ECLAM,
SLAM b415 Blood vessel functions
Pancreatitis SLAM s550 Structure of pancreas
Peritonitis ECLAM, SLAM b28012 Pain in stomach or abdomen
Renal Nephrotic syndrome BILAG b6100 Kidneys
b54500 Water retention
Table 1 Continued
Organ System Symptom Score ICF Description
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Empirical study
A world-spanning multi-centre cross-sectional study
of individuals will identify ICF categories relevant for
patients with SLE. The ICF Checklist,22 the SF-36,23 a
questionnaire for socio-demographic variables, and
additional items derived from the literature review will
be used for this study. Health status measures identi-
fied in literature reviews will be linked to the ICF.18
These empirical studies will likewise start in October
2006, with results available by February 2007.
Conclusions
In embarking on the project to define ICF Core Sets for
SLE, we here have described the background and the
approach for development of both a Comprehensive
and a Brief ICF Core Set for SLE. It is interesting, in
this regard, that SLE activity scores include important
information on some features of the disease, which
link to the components body functions and body struc-
tures of the ICF classification (Table 1). However, it is
likewise obvious that there is no one-to-one linkage,
demonstrating systematic differences in the approach,
and that some symptoms could not be linked to an ICF
category. Moreover, when considering the patient per-
spective, we may also need to assess the other compo-
nents, namely the individuals’ functioning in daily life
and social participation. Since functioning and partici-
pation in daily living contribute significantly to the
quality of life, they are highly relevant aspects for the
comprehensive assessment of a patient with SLE.
Comprehensive assessment and understanding of
individual daily problems requires a strong focus on
patient perspectives, which most likely differ between
cultures. The ICF includes the environment as a con-
textual factor, which also differs between countries and
cultures. Therefore, this project will accommodate this
international perspective both in the selection of loca-
tions for patient focus groups and the participation of
additional experts for the Delphi exercise.
The development of the SLE ICF Core Sets will be
an inclusive and open process. We therefore encourage
both SLE clinical experts and SLE patient representa-
tives to actively participate in the process. Individuals,
institutions and associations, can be formally associ-
ated as partners of the project. Everybody interested
should please contact the project coordinators (MA,
TS, DP). We believe that it is time develop the tools to
assess the life of patients with SLE with greater clarity
precision and thereby promote treatments to enhance
their quality of life.
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